Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials-Reference-Cited by-同舟云学术

Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials

Published:2016-03-10 Issue:1 Volume:17 Page:
ISSN:2050-6511
Container-title:BMC Pharmacology and Toxicology
language:en
Short-container-title:BMC Pharmacol Toxicol

Author:

Wiśniowska Barbara,Tylutki Zofia,Wyszogrodzka Gabriela,Polak Sebastian^ORCID

Funder

Polish National Science Center

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1186/s40360-016-0053-1

Reference162 articles.

1. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138:470–84.

2. Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the critical path initiative. Am Heart J. 2009;158:317–26.

3. Redfern WS, Ewart L, Hammond TG, et al. Impact and frequency of different toxicities throughout pharmaceutical life cycle. Toxicologist. 2010;S1:1081.

4. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111–26.

5. Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci. 2011;120:14–32.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib;Clinical and Translational Science;2024-09

2. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023;Frontiers in Pharmacology;2024-07-17

3. A novel degradable PEG superparamagnetic iron oxide capsule coupled with a polyphenolic nano-enzymatic conjugate (PSPM-NE), to treat ROS-driven cardiovascular-diseases, tested in atherosclerosis as a model disease, and hypothesizing autoimmunity as an atheroma's trigger;Frontiers in Cardiovascular Medicine;2024-07-02

4. Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants;Clinical Pharmacology in Drug Development;2024-04-16

5. The posterity of Zebrafish in paradigm of in vivo molecular toxicological profiling;Biomedicine & Pharmacotherapy;2024-02